The rapid growth of private testosterone prescribing is raising alarm among clinicians, who warn that treatment is creeping beyond men with a clearly defined medical need toward a far wider group reporting vague, nonspecific symptoms. Borderline test results, combined with aggressive marketing, are pushing some patients toward hormone therapy they may not require — and may not benefit from.
Testosterone replacement is a legitimate treatment for men whose bodies genuinely fail to produce enough of the hormone, a condition known as hypogonadism. But the boundary between a genuine deficiency and a normal age-related decline has become blurred, and the commercial incentives of private clinics can encourage overdiagnosis. The consequences stretch beyond the individual: unnecessary prescriptions expose patients to cardiovascular and other risks while adding pressure to an already strained public health system. Experts are calling for clearer diagnostic standards and tighter oversight so that genuine need, rather than marketing, drives who receives treatment. Until those safeguards arrive, the onus falls on patients to ask searching questions about whether the therapy they are being offered is truly necessary — and on regulators to decide how far the boundaries of a commercial market should be allowed to stretch.
